Oxford's adoption of Olink tech to 'unravel mechanisms of disease'

10 May 2022

Sweden’s Olink Holding (Nasdaq: OLK) has announced that Oxford Genomics at the University of Oxford is adopting its technology, becoming the UK’s first Olink lab.

It is hoped that the partnership will enable new techniques to unravel mechanisms of disease using the Olink Explore platform.

"We are trying to make the drug development process more precise by understanding the heterogeneity in the patients instead of one drug fits all"According to the Uppsala-based company, in the developing age of multi-omic analysis, to truly understand the linkage between disease and phenotype, proteomics is an essential tool.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK